| Author
|
Subject group
|
n
|
BIA- parameter
|
Instrument
|
Comments/ appreciation
|
Limitations
|
| Sanchez-Lara et al. [86] |
Advanced Non-Small-Cell Lung Cancer |
119 |
PhA |
RJL |
Patient with Phase angle ≤5.8° has significant (p<0.01) poor survival. |
Controlled clinical trial |
| Malecka-Massalska et al. [87]
|
Head and neck cancer
Healthy volunteers |
28
28 |
PhA |
ImpediMed
BIA |
Mean vectors of H and NC group vs. the control group were characterized by an increased normalized resistance component with a reduced reactance component (separate 95% confidence limits, P<0.05), indicating a decreased ionic conduction (dehydration) with loss of dielectric mass (cell membranes and tissue interfaces) of soft tissue. |
Controlled clinical trial |
| Norman et al. [88] |
Cancer |
399 |
PhA |
BIA |
Patients with a phase angle ≤ 5° had significantly lower nutritional and functional status, impaired quality of life (P lt 0.0001), and increased mortality (P lt 0.001). |
Controlled clinical trial |
| Paiva et al. [89] |
Cancer |
195 |
PhA |
BIA |
The present study demonstrates that PA, used as SPA, is an independent prognostic indicator. Patients with PA < -1.65° still presented a higher mortality rate (RR 2.35 CI: 1.41-3.90; p = 0.001). |
Prospective cohort |
| Santarpia et al. [90] |
Advanced cancer |
13 |
PhA |
BIA |
Phase angle =0.384, P=0.024) was found to be strictly related to survival time and can be therefore considered a prognostic tool in patients with advanced cancer. |
prospective study: small sample size |
| Davis et al. [91] |
Advanced cancer |
50 |
PhA |
underwent BIA |
Weight loss was associated with shorter survival. A higher phase angle (PA) on day 1 predicted longer survival. Increased PA during hydration predicted shorter survival: increased weight during hydration predicted longer survival. An increase in phase angle during hydration predicted poorer survival and preexisting intracellular dehydration, cachexia, or poor membrane function. |
Controlled clinical trial |
| Gupta et al. [92] |
advanced NSCLC |
165 |
PhA |
BIA |
Patients with phase angle ≤ 5.3° had a median survival of 7.6 months (95% CI: 4.7 to 9.5; n = 81), while those with > 5.3° had 12.4 months (95% CI: 10.5 to 18.7; n = 84); (p = 0.02). Every one degree increase in phase angle was associated with a relative risk of 0.79 (95% CI: 0.64 to 0.97, P = 0.02).
N.P. Nutritional interventions targeted at improving phase angle could potentially lead to an improved survival in patients with advanced non-small cell lung cancer (advanced NSCLC). |
Prospective clinical trial |
